Previous 10 | Next 10 |
All MDS-UPDRS Part I, II, III, IV sub-scores improved, including substantial majority of individual items between 71% and 92% SIGMAR1 mRNA expression significantly increased in ANAVEX ® 2-73-treated patients vs placebo (p=0.035) and was significantly associated with imp...
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dis...
Because many receptors and factors lead to the onset and early progression of Alzheimer's disease, targeting any one of them only slightly slows down the progression of Alzheimer's in subgroups. Targeting intervening points between receptor overactivation and peroxynitrite formation, ...
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dis...
Cassava Sciences may have removed an outlier in the drug group turning a negative result into a positive one, leading to a windfall for its CEO and chief scientific investigator. Cassava Sciences stated mechanisms of action do not explain its results. Simufilam may be a sigma-1 re...
Image source: The Motley Fool. Anavex Life Sciences (NASDAQ: AVXL) Q1 2022 Earnings Call Feb 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Anavex Life Sciences (AVXL) Q1 2022 Earnings Call Transcript
Anavex Life Sciences (NASDAQ:AVXL) CEO Christopher Missling used the company's fiscal Q1 2022 call after the bell yesterday to address questions surrounding results of phase 3 data for Rett syndrome candidate ANAVEX2-73 that some criticized and which led to a stock decline earlier this m...
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
Anavex Life Sciences Corp. (AVXL) Q1 2022 Earnings Conference Call February 9, 2022 04:30 PM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer. Conference Call Participants ...
Anavex Life Sciences press release (NASDAQ:AVXL): FQ1 GAAP EPS of -$0.14. Cash and cash equivalents of $151.1 million on December 31, 2021, compared to $152.1 million on September 30, 2021. For further details see: Anavex Life Sciences GAAP EPS of -$0.14
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...